中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2013年
10期
768-771
,共4页
窦亚玲%祁晓莉%辛论%陈东%张海青%崔全才
竇亞玲%祁曉莉%辛論%陳東%張海青%崔全纔
두아령%기효리%신론%진동%장해청%최전재
癌,非小细胞肺%基因,erbB-1%突变%DNA探针
癌,非小細胞肺%基因,erbB-1%突變%DNA探針
암,비소세포폐%기인,erbB-1%돌변%DNA탐침
Carcinoma,non-small-cell lung%Genes,erbB-1%Mutation%DNA probes
目的 探讨TaqMan扩增阻滞突变系统(ARMS)法检测非小细胞肺癌(NSCLC)组织表皮生长因子受体(EGFR)基因突变的价值.方法 收集2008年1月至2011年3月,北京4家三级甲等医院的199例NSCLC患者外科手术切除的肺部肿瘤组织预留石蜡样本,比较TaqMan-ARMS法和DNA测序法检测EGFR外显子19和21(EGFR19和EGFR21)的突变情况.结果 TaqMan-ARMS法检测的EGFR19和EGFR21总突变率为19.1％ (38/199),按不同病理类型分:腺癌35.0％ (36/103),鳞癌2.2％ (2/93),腺鳞癌0；而DNA测序法检测的EGFR19和EGFR21总突变率为19.6％ (39/199),按不同病理类型分:腺癌35.9％(37/103),鳞癌2.2％(2/93),腺鳞癌0.两种方法检测的NSCLC患者EGFR基因突变率差异无统计学意义,具有高度一致性(P=1.000,κ=0.984).两种方法检测的腺癌组织EGFR基因的突变率均高于鳞癌和腺鳞癌.结论 TaqMan-ARMS法与DNA测序法在检测NSCLC组织的EGFR基因突变上具有较好的一致性.
目的 探討TaqMan擴增阻滯突變繫統(ARMS)法檢測非小細胞肺癌(NSCLC)組織錶皮生長因子受體(EGFR)基因突變的價值.方法 收集2008年1月至2011年3月,北京4傢三級甲等醫院的199例NSCLC患者外科手術切除的肺部腫瘤組織預留石蠟樣本,比較TaqMan-ARMS法和DNA測序法檢測EGFR外顯子19和21(EGFR19和EGFR21)的突變情況.結果 TaqMan-ARMS法檢測的EGFR19和EGFR21總突變率為19.1％ (38/199),按不同病理類型分:腺癌35.0％ (36/103),鱗癌2.2％ (2/93),腺鱗癌0；而DNA測序法檢測的EGFR19和EGFR21總突變率為19.6％ (39/199),按不同病理類型分:腺癌35.9％(37/103),鱗癌2.2％(2/93),腺鱗癌0.兩種方法檢測的NSCLC患者EGFR基因突變率差異無統計學意義,具有高度一緻性(P=1.000,κ=0.984).兩種方法檢測的腺癌組織EGFR基因的突變率均高于鱗癌和腺鱗癌.結論 TaqMan-ARMS法與DNA測序法在檢測NSCLC組織的EGFR基因突變上具有較好的一緻性.
목적 탐토TaqMan확증조체돌변계통(ARMS)법검측비소세포폐암(NSCLC)조직표피생장인자수체(EGFR)기인돌변적개치.방법 수집2008년1월지2011년3월,북경4가삼급갑등의원적199례NSCLC환자외과수술절제적폐부종류조직예류석사양본,비교TaqMan-ARMS법화DNA측서법검측EGFR외현자19화21(EGFR19화EGFR21)적돌변정황.결과 TaqMan-ARMS법검측적EGFR19화EGFR21총돌변솔위19.1％ (38/199),안불동병리류형분:선암35.0％ (36/103),린암2.2％ (2/93),선린암0；이DNA측서법검측적EGFR19화EGFR21총돌변솔위19.6％ (39/199),안불동병리류형분:선암35.9％(37/103),린암2.2％(2/93),선린암0.량충방법검측적NSCLC환자EGFR기인돌변솔차이무통계학의의,구유고도일치성(P=1.000,κ=0.984).량충방법검측적선암조직EGFR기인적돌변솔균고우린암화선린암.결론 TaqMan-ARMS법여DNA측서법재검측NSCLC조직적EGFR기인돌변상구유교호적일치성.
Objective To explore the value of detecting mutations on epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) tissue by TaqMan-amplification refractory mutation system (TaqMan-ARMS).Methods TaqMan-ARMS and DNA sequencing were used to detect the EGFR exon 19 and 21 mutations in tumor tissues and the samples collected from 199 patients at 4 different 3A hospitals in Beijing from January 2008 to March 2011.Results The rate of mutations in EGFR exon 19 and 21 was 19.1％ (38/199),according to their different pathological types.Based upon TaqMan-ARMS,the classification was as followed:adenocarcinoma (35.0％ (36/103)),squamous carcinoma (2.2％ (2/93)) and adenosquamous carcinoma (0).According to DNA sequencing,they were 19.6％ (39/199),35.9％ (37/103),2.2％ (2/93) and 0 respectively.Thus,no statistically significant difference existed between two methods (McNemar Test,P =1.000,κ =0.984).The mutation rate of adenocarcinoma was higher than those of squamous and adenosquamous carcinoma.Conclusion The detection of EGFR mutations is highly consistent in the NSCLC tissue by the methods of TaqMan-ARMS and DNA sequencing.
